Predictive value of 18 F-FDG PET in patients with advanced medullary thyroid carcinoma treated with vandetanib

Rudolf A. Werner, Jan Stefan Schmid, Takahiro Higuchi, Mehrbod S. Javadi, Steven P. Rowe, Bruno Märkl, Christoph Aulmann, Martin Fassnacht, Matthias Kroiss, Christoph Reiners, Andreas K. Buck, Michael C. Kreissl, Constantin Lapa

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Therapeutic options in advanced medullary thyroid carcinoma (MTC) have markedly improved since the introduction of tyrosine kinase inhibitors (TKIs). We aimed to assess the role of metabolic imaging using 18 F-FDG PET/CT shortly before and 3 mo after initiation of TKI treatment. Methods: Eighteen patients with advanced and progressive MTC scheduled for vandetanib treatment underwent baseline 18 F-FDG PET/CT before and 3 mo after TKI treatment initiation. During follow-up, CT scans were obtained every 3 mo and analyzed according to RECIST. The predictive value for estimating progression-free survival (PFS) and overall survival (OS) was examined by investigating the 18 F-FDG SUV mean/max of the metabolically most active lesion, as well as by analyzing clinical parameters (tumor marker doubling times [calcitonin, carcinoembryonic antigen], prior therapies, rearranged-during-transfection mutational status, and disease type). Results: Within a median follow-up of 5.2 y, 9 patients experienced disease progression after a median interval of 2.1 y, whereas the remainder had ongoing disease control (5 with a partial response and 4 with stable disease). Eight of the 9 patients with progressive disease died from MTC after a median of 3.5 y after TKI initiation. A pretherapeutic SUV mean of more than 4.0 predicted a significantly shorter PFS (1.9 y vs. 5.2 y, P = 0.04). Furthermore, sustained high 18 F-FDG uptake at 3 mo with a SUV mean of more than 2.8 tended to portend an unfavorable prognosis, with a PFS of 1.9 y (vs. 3.5 y, P = 0.3). Prolonged carcinoembryonic antigen doubling times were significantly correlated with longer PFS (r = 0.7) and OS (r = 0.76, P, 0.01). None of the other clinical parameters had prognostic significance. Conclusion: Pretherapeutic 18 F-FDG PET/CT provides prognostic information in patients with advanced MTC scheduled for treatment with the TKI vandetanib. A low tumor metabolism with an SUV mean of less than 4.0 before treatment predicts a longer PFS.

Original languageEnglish
Pages (from-to)756-761
Number of pages6
JournalJournal of Nuclear Medicine
Volume59
Issue number5
DOIs
Publication statusPublished - May 1 2018
Externally publishedYes

Fingerprint

Protein-Tyrosine Kinases
Disease-Free Survival
Carcinoembryonic Antigen
Therapeutics
Survival
Calcitonin
Tumor Biomarkers
N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine
Medullary Thyroid cancer
Transfection
Disease Progression
Neoplasms

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Predictive value of 18 F-FDG PET in patients with advanced medullary thyroid carcinoma treated with vandetanib . / Werner, Rudolf A.; Schmid, Jan Stefan; Higuchi, Takahiro; Javadi, Mehrbod S.; Rowe, Steven P.; Märkl, Bruno; Aulmann, Christoph; Fassnacht, Martin; Kroiss, Matthias; Reiners, Christoph; Buck, Andreas K.; Kreissl, Michael C.; Lapa, Constantin.

In: Journal of Nuclear Medicine, Vol. 59, No. 5, 01.05.2018, p. 756-761.

Research output: Contribution to journalArticle

Werner, RA, Schmid, JS, Higuchi, T, Javadi, MS, Rowe, SP, Märkl, B, Aulmann, C, Fassnacht, M, Kroiss, M, Reiners, C, Buck, AK, Kreissl, MC & Lapa, C 2018, ' Predictive value of 18 F-FDG PET in patients with advanced medullary thyroid carcinoma treated with vandetanib ', Journal of Nuclear Medicine, vol. 59, no. 5, pp. 756-761. https://doi.org/10.2967/jnumed.117.199778
Werner, Rudolf A. ; Schmid, Jan Stefan ; Higuchi, Takahiro ; Javadi, Mehrbod S. ; Rowe, Steven P. ; Märkl, Bruno ; Aulmann, Christoph ; Fassnacht, Martin ; Kroiss, Matthias ; Reiners, Christoph ; Buck, Andreas K. ; Kreissl, Michael C. ; Lapa, Constantin. / Predictive value of 18 F-FDG PET in patients with advanced medullary thyroid carcinoma treated with vandetanib In: Journal of Nuclear Medicine. 2018 ; Vol. 59, No. 5. pp. 756-761.
@article{c3baf995e1014018beafb4d9618de8a1,
title = "Predictive value of 18 F-FDG PET in patients with advanced medullary thyroid carcinoma treated with vandetanib",
abstract = "Therapeutic options in advanced medullary thyroid carcinoma (MTC) have markedly improved since the introduction of tyrosine kinase inhibitors (TKIs). We aimed to assess the role of metabolic imaging using 18 F-FDG PET/CT shortly before and 3 mo after initiation of TKI treatment. Methods: Eighteen patients with advanced and progressive MTC scheduled for vandetanib treatment underwent baseline 18 F-FDG PET/CT before and 3 mo after TKI treatment initiation. During follow-up, CT scans were obtained every 3 mo and analyzed according to RECIST. The predictive value for estimating progression-free survival (PFS) and overall survival (OS) was examined by investigating the 18 F-FDG SUV mean/max of the metabolically most active lesion, as well as by analyzing clinical parameters (tumor marker doubling times [calcitonin, carcinoembryonic antigen], prior therapies, rearranged-during-transfection mutational status, and disease type). Results: Within a median follow-up of 5.2 y, 9 patients experienced disease progression after a median interval of 2.1 y, whereas the remainder had ongoing disease control (5 with a partial response and 4 with stable disease). Eight of the 9 patients with progressive disease died from MTC after a median of 3.5 y after TKI initiation. A pretherapeutic SUV mean of more than 4.0 predicted a significantly shorter PFS (1.9 y vs. 5.2 y, P = 0.04). Furthermore, sustained high 18 F-FDG uptake at 3 mo with a SUV mean of more than 2.8 tended to portend an unfavorable prognosis, with a PFS of 1.9 y (vs. 3.5 y, P = 0.3). Prolonged carcinoembryonic antigen doubling times were significantly correlated with longer PFS (r = 0.7) and OS (r = 0.76, P, 0.01). None of the other clinical parameters had prognostic significance. Conclusion: Pretherapeutic 18 F-FDG PET/CT provides prognostic information in patients with advanced MTC scheduled for treatment with the TKI vandetanib. A low tumor metabolism with an SUV mean of less than 4.0 before treatment predicts a longer PFS.",
author = "Werner, {Rudolf A.} and Schmid, {Jan Stefan} and Takahiro Higuchi and Javadi, {Mehrbod S.} and Rowe, {Steven P.} and Bruno M{\"a}rkl and Christoph Aulmann and Martin Fassnacht and Matthias Kroiss and Christoph Reiners and Buck, {Andreas K.} and Kreissl, {Michael C.} and Constantin Lapa",
year = "2018",
month = "5",
day = "1",
doi = "10.2967/jnumed.117.199778",
language = "English",
volume = "59",
pages = "756--761",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "5",

}

TY - JOUR

T1 - Predictive value of 18 F-FDG PET in patients with advanced medullary thyroid carcinoma treated with vandetanib

AU - Werner, Rudolf A.

AU - Schmid, Jan Stefan

AU - Higuchi, Takahiro

AU - Javadi, Mehrbod S.

AU - Rowe, Steven P.

AU - Märkl, Bruno

AU - Aulmann, Christoph

AU - Fassnacht, Martin

AU - Kroiss, Matthias

AU - Reiners, Christoph

AU - Buck, Andreas K.

AU - Kreissl, Michael C.

AU - Lapa, Constantin

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Therapeutic options in advanced medullary thyroid carcinoma (MTC) have markedly improved since the introduction of tyrosine kinase inhibitors (TKIs). We aimed to assess the role of metabolic imaging using 18 F-FDG PET/CT shortly before and 3 mo after initiation of TKI treatment. Methods: Eighteen patients with advanced and progressive MTC scheduled for vandetanib treatment underwent baseline 18 F-FDG PET/CT before and 3 mo after TKI treatment initiation. During follow-up, CT scans were obtained every 3 mo and analyzed according to RECIST. The predictive value for estimating progression-free survival (PFS) and overall survival (OS) was examined by investigating the 18 F-FDG SUV mean/max of the metabolically most active lesion, as well as by analyzing clinical parameters (tumor marker doubling times [calcitonin, carcinoembryonic antigen], prior therapies, rearranged-during-transfection mutational status, and disease type). Results: Within a median follow-up of 5.2 y, 9 patients experienced disease progression after a median interval of 2.1 y, whereas the remainder had ongoing disease control (5 with a partial response and 4 with stable disease). Eight of the 9 patients with progressive disease died from MTC after a median of 3.5 y after TKI initiation. A pretherapeutic SUV mean of more than 4.0 predicted a significantly shorter PFS (1.9 y vs. 5.2 y, P = 0.04). Furthermore, sustained high 18 F-FDG uptake at 3 mo with a SUV mean of more than 2.8 tended to portend an unfavorable prognosis, with a PFS of 1.9 y (vs. 3.5 y, P = 0.3). Prolonged carcinoembryonic antigen doubling times were significantly correlated with longer PFS (r = 0.7) and OS (r = 0.76, P, 0.01). None of the other clinical parameters had prognostic significance. Conclusion: Pretherapeutic 18 F-FDG PET/CT provides prognostic information in patients with advanced MTC scheduled for treatment with the TKI vandetanib. A low tumor metabolism with an SUV mean of less than 4.0 before treatment predicts a longer PFS.

AB - Therapeutic options in advanced medullary thyroid carcinoma (MTC) have markedly improved since the introduction of tyrosine kinase inhibitors (TKIs). We aimed to assess the role of metabolic imaging using 18 F-FDG PET/CT shortly before and 3 mo after initiation of TKI treatment. Methods: Eighteen patients with advanced and progressive MTC scheduled for vandetanib treatment underwent baseline 18 F-FDG PET/CT before and 3 mo after TKI treatment initiation. During follow-up, CT scans were obtained every 3 mo and analyzed according to RECIST. The predictive value for estimating progression-free survival (PFS) and overall survival (OS) was examined by investigating the 18 F-FDG SUV mean/max of the metabolically most active lesion, as well as by analyzing clinical parameters (tumor marker doubling times [calcitonin, carcinoembryonic antigen], prior therapies, rearranged-during-transfection mutational status, and disease type). Results: Within a median follow-up of 5.2 y, 9 patients experienced disease progression after a median interval of 2.1 y, whereas the remainder had ongoing disease control (5 with a partial response and 4 with stable disease). Eight of the 9 patients with progressive disease died from MTC after a median of 3.5 y after TKI initiation. A pretherapeutic SUV mean of more than 4.0 predicted a significantly shorter PFS (1.9 y vs. 5.2 y, P = 0.04). Furthermore, sustained high 18 F-FDG uptake at 3 mo with a SUV mean of more than 2.8 tended to portend an unfavorable prognosis, with a PFS of 1.9 y (vs. 3.5 y, P = 0.3). Prolonged carcinoembryonic antigen doubling times were significantly correlated with longer PFS (r = 0.7) and OS (r = 0.76, P, 0.01). None of the other clinical parameters had prognostic significance. Conclusion: Pretherapeutic 18 F-FDG PET/CT provides prognostic information in patients with advanced MTC scheduled for treatment with the TKI vandetanib. A low tumor metabolism with an SUV mean of less than 4.0 before treatment predicts a longer PFS.

UR - http://www.scopus.com/inward/record.url?scp=85046397643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046397643&partnerID=8YFLogxK

U2 - 10.2967/jnumed.117.199778

DO - 10.2967/jnumed.117.199778

M3 - Article

C2 - 29025983

AN - SCOPUS:85046397643

VL - 59

SP - 756

EP - 761

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 5

ER -